drug development

Incannex Healthcare wins MedTech Breakthrough Award for IHL-42X sleep apnea therapy, validated by successful Phase 2 trial results showing significant improvements in key endpoints.

Zealand Pharma reports strong Q1 2026 results with obesity treatment advances, $700M collaboration revenue, and $200M share buyback program.

ABLi Therapeutics appoints Dr. Rachelle Doody, Roche neurology veteran, to board as company advances risvodetinib into Phase 3 trials for Parkinson's and related diseases.

Soleno Therapeutics faces class action lawsuit alleging false statements about DCCR drug safety. Lead plaintiff deadline: May 5, 2026.

Pfizer's 50% stock decline masks a 6.4% dividend yield and strategic repositioning in GLP-1 drugs, oncology, and migraine treatments, offering potential upside for patient investors.

ProQR Therapeutics nominates Boehringer Ingelheim's Chief Medical Officer Dr. Lykke Hinsch Gylvin to its Board, pending shareholder approval.

FDA launches real-time clinical trial initiative with $AMGN and $AZN pilots, aiming to accelerate drug approvals and eliminate traditional reporting delays.

DelveInsight's 2026 report shows robust rheumatoid arthritis pipeline with 75+ players developing 80+ drugs, featuring novel JAK and BTK inhibitors plus cell-based therapies.

Global biosimulation market projected to expand from $4.7B in 2025 to $20B by 2034 at 17% CAGR, driven by regulatory support and virtual trial adoption.

Trump's April 2026 executive order grants FDA priority vouchers to psychedelic biotech firms, triggering stock surges for Compass Pathways, AtaiBeckley, and Definium Therapeutics amid speculative valuations.

Wall Street projects 170% upside for Viking Therapeutics' obesity drug candidate VK2735, citing superior weight loss and tolerability versus Novo Nordisk and Eli Lilly rivals.

Over 65 pharma companies advance 75+ COPD drugs, shifting from traditional bronchodilators to targeted biologics as AstraZeneca's tozorakimab validates new approaches.

Nurix Therapeutics unveils preclinical data showing protein degradation pipeline effectiveness, with NRX-0305 achieving 142% lifespan extension in melanoma models.

Royalty Pharma launches $1M annual award recognizing translational medicine breakthroughs, to be presented starting spring 2027 at Accelerating Bio-Innovation conference chaired by Nobel Laureate Sir Gregory Winter.

Over 45 companies are developing 50+ follicular lymphoma therapies, with major pharma players advancing 5+ late-stage candidates using diverse mechanisms including protein degraders and kinase inhibitors.

Bispecific antibody market projected to reach $60 billion by 2031 from $16 billion in 2025, with 550+ clinical trials and 18 approved drugs driving sector transformation.

Targeted alpha therapy market surging with 30+ drugs in clinical trials. Major pharma M&A signals confidence in precision oncology's future.

Global life sciences consulting market projected to reach $29.6B by 2034 from $14.1B in 2024, driven by AI adoption and biotech expansion.

Over 100 pharmaceutical companies compete to develop 120+ NSCLC pipeline drugs, with 30+ in late-stage trials. Precision oncology advances drive innovation in biomarker-selected populations.

Eli Lilly acquires Centessa Pharmaceuticals for $6.3B, gaining neuroscience assets. Stock rises on strong financial footing from weight-loss drug success.